References
- 1. Wilkinson JM, Harris MA, Davidson SE, et al. A retrospective study of bladder morbidity in patients receiving intracavitary brachytherapy as all or part of their treatment for cervix cancer. Br J Radiol. 2003;76:897–903.10.1259/bjr/6875621314711778
- 2. Garbaulet A, Porter R, Mazeron JJ, et al. The GEC ESTRO Handbook of Brachytherapy. 2002;20:473-480.
- 3. Viswanathan AN, Thomadsen B. American Brachytherapy Society concensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy. 2012;11(1): 33-46.
- 4. De Leeuw AA, Moerland MA, Nomden C, et al. Applicator reconstruction and applicator shifts in 3D MR-based PDR brachytherapy of cervical cancer. Radiother. Oncol. 2009;93:341–346.
- 5. Kertzscher G, Rosenfield A, Beddar S, et al. In vivo dosimetry: Trends and prospects for radiotherapy. Br J Radiol. 2014;87(1041):201-206.10.1259/bjr.20140206445315125007037
- 6. International Atomic Energy Agency TRS 398 protocol. Implementation of the international code of practice on dosimetry in radiotherapy (TRS 398): Review of testing results. IAEA-TECDOC, 2010:978-92-0-100610-3.
- 7. Shima K, Tateoka K, Saitoh Y, et al. Analysis of post-exposure density growth in radiochromic film with respect to the radiation dose. J Radiat Res, 2012;53(2):301-305.10.1269/jrr.1109122245751
- 8. Saur S, Frengen J. Gafchromic EBT film dosimetry with flatbed CCD scanner: a novel background correction method and full dose uncertainty analysis. Medical Physics, (2008); 35(7):3094–3101.10.1118/1.293852218697534
- 9. van Battum LJ, Hoffmans D, Piersma H, et al. Accurate dosimetry with GafChromic EBT film of a 6 MV photon beam in water: what level is achievable? Medical Physics, (2008);35(2): 704–716.10.1118/1.282819618383692
- 10. Karsch L, Beyreuther E, Burris-Mog T, et al. Dose rate dependence for different dosimeters and detectors. Med. Phys. 2012;39(5):2447-2455.
- 11. Carrara M, Romanyukha A, Tenconi C, et al. Clinical application of MOSkin dosimeters to rectal wall in vivo dosimetry in gynecological HDR brachytherapy. Physica Medica: European Journal of Medical Physics. 2017;41:5–12.10.1016/j.ejmp.2017.05.00328499627
- 12. Kertzscher G, Andersen CE, Siebert FA, et al. Identifying afterloading PDR and HDR brachytherapy errors using real-time fibre-coupled Al2O3:C dosimetry and a novel statistical error decision criterion. Radiother. Oncol. 2011;100:456–462.
- 13. Tanderup K, Beddar S, Andersen CE, et al. In vivo dosimetry in brachytherapy. Medical Physics, 2013;40(7):070902-15.10.1118/1.481094323822403
- 14. Milickovic N, Mavroidis P, Tselis N, et al. 4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery. Med. Phys. 2011;38:4982–4993.
- 15. Reniers B, Landry G, Eichner R, et al. In vivo dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: Feasibility study. Med. Phys. 2012;39:1925–1935.
- 16. Kutcher GJL, Coia M, Gillin WF, et al. Comprehensive QA for radiation oncology: Report of AAPM Radiation Therapy Committee Task Group 40. Med. Phys. 1994;21(4):581-61.
- 17. Allahverdi M, Sarkhosh M, Aghili M, et al. Evaluation of treatment planning system of brachytherapy according to dose to the rectum delivered. Radiat. Prot. Dosim. 2012;150:312–315.10.1093/rpd/ncr41522128355
- 18. Seymour EL, Downes SJ, Fogarty GB, et al. In vivo real-time dosimetric verification in high dose rate prostate brachytherapy,” Med. Phys. 2011;38:4785–4794.
- 19. Waldhäusl C, Wambersie A, Potter R, and Georg D. In-vivo dosimetry for gynaecological brachytherapy: Physical and clinical considerations. Radiother. Oncol. 2005;77:310–317.
- 20. Chao KS, Perez CA, Brady LW. Physics and Dosimetry of High-Dose-Rate Brachytherapy in Radiation Oncology Management Decisions (2nd Edition). Lippincott Williams & Wilkins. Philadelphia. 2002;89–94.
- 21. Ballester F, Granero D, Perez-Calatyud J, Casal E, Agramunt S, Cases R. Monte Carlo dosimetric study of the BEBIG Co-60 HDR source. Phys Med Biol. 2005;50:N309–16.10.1088/0031-9155/50/21/N0316237230